Communiqués Allogene Therapeutics, Inc.

Actions

ALLO

US0197701065

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 31/07/2026			Varia. 5j.	Varia. 1 janv.
1,880 ^USD	-4,57%		+8,05%	+37,23%

29/07	Le cemacabtagene ansegedleucel d'Allogene Therapeutics reçoit les désignations RMAT et Fast Track de la FDA	MT
29/07	Allogene Therapeutics reçoit les désignations RMAT et Fast Track de la FDA pour le cemacabtagene ansegedleucel en traitement de consolidation de première ligne du lymphome à grands cellules B	CI

Communiqués

30/07	Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for Cemacabtagene Ansegedleucel as First-Line Consolidation Therapy for Large B-Cell Lymphoma	AQ
29/07	Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma	GL
15/07	Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors	GL
28/05	Allogene Therapeutics Announces Planned CEO Succession	GL
26/05	Allogene Therapeutics Announces Participation in Upcoming Investor Conferences	GL
13/05	Allogene Therapeutics: Q1 Earnings Snapshot	AQ
13/05	Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update	GL
06/05	Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update	GL
21/04	Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia	GL
20/04	Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026	GL
16/04	Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock	GL
16/04	Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock	AQ
15/04	Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases	GL
15/04	Allogene Therapeutics Announces Pricing of Public Offering of Common Stock	GL
13/04	Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock	GL
13/04	Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel in First-Line Consolidation LBCL on Monday, April 13, 2026	AQ
13/04	Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL	GL
10/04	Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026	GL
12/03	Allogene Therapeutics : Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update	PU
12/03	Allogene Therapeutics: Q4 Earnings Snapshot	AQ
12/03	Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update	GL
02/03	Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update	GL
05/02	Allogene Therapeutics Announces Participation in Upcoming Investor Conferences	GL
08/01	Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T	GL
15/12	Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis	GL